WST — West Pharmaceutical Services Inc. stock price and chart

WST

West Pharmaceutical Services Inc.Stock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.04% · Russell 1000 0.04% · US Stock Market 0.04% · Russell 3000 0.03% · MSCI World 0.03% · MSCI ACWI 0.02%

$362.31-1.17%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

100.0150.0200.0250.0300.0350.0400.0450.0010.0M20.0M$362.31

2026-09-18

Price$362.31

MA20$330.44

MA50$286.96

Vol3.5M

What would $1,000 invested in WST be worth today? →

WST returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $362.31
Change YTD: +31.68%
Next earnings: Oct 22, 2026
Market cap: 25.5B2016-09 5.5B2026-09 25.5B+367.7% over the window
Enterprise value: 25.4B
Shares outstanding: 70.4M2016-06 73.2M2026-06 70.4M-3.9% over the window
52W low: $223.83
52W high: $386.00
From 52W high: -6.14%
From 52W low: +61.87%
52W range: 85%
Beta: 1.13

Volume

Rel volume: 2.75×
30D volume: 527.1K
30D $ vol: 184.9M

Fundamentals

Sales (ttm): 3.3B2016-06 1.5B2026-06 3.3B+128.8% over the window
Sales/share: $47.272016-06 $19.862026-06 $47.27+138.0% over the window
EPS (ttm): $7.822016-06 $1.372026-06 $7.82+471.2% over the window
FCF (ttm): 436.9M2016-06 67.5M2026-06 436.9M+547.3% over the window
FCF/share: $6.212016-06 $0.922026-06 $6.21+573.4% over the window
Book value/share: $42.492016-06 $15.152026-06 $42.49+180.4% over the window
Net margin: 16.98%2016-06 7.0%2026-06 17.0%+142.8% over the window
ROE: 18.89%2016-06 9.2%2026-06 18.9%+106.1% over the window
ROA: 13.86%2016-06 6.0%2026-06 13.9%+132.3% over the window
Debt / equity: 0.07×2016-06 0.212026-06 0.07-67.1% over the window
Current ratio: 2.822016-06 2.752026-06 2.82+2.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +12.39%2025-06-30 → 2026-06-303B → 3.3B (+12.4% total)+5.09%2023-06-30 → 2026-06-302.9B → 3.3B (+16.1% total)+5.69%2021-06-30 → 2026-06-302.5B → 3.3B (+31.9% total)+8.63%2016-06-30 → 2026-06-301.5B → 3.3B (+128.8% total)
Net income: +15.84%2025-06-30 → 2026-06-30487.7M → 564.9M (+15.8% total)+2.88%2023-06-30 → 2026-06-30518.7M → 564.9M (+8.9% total)+1.70%2021-06-30 → 2026-06-30519.2M → 564.9M (+8.8% total)+18.71%2016-06-30 → 2026-06-30101.7M → 564.9M (+455.5% total)
FCF: +27.03%2025-06-30 → 2026-06-30344M → 436.9M (+27.0% total)+3.26%2023-06-30 → 2026-06-30396.8M → 436.9M (+10.1% total)+9.03%2021-06-30 → 2026-06-30283.6M → 436.9M (+54.1% total)+20.54%2016-06-30 → 2026-06-3067.5M → 436.9M (+547.3% total)
Shares: -2.13%2025-06-30 → 2026-06-3071.9M → 70.4M (-2.1% total)-1.60%2023-06-30 → 2026-06-3073.9M → 70.4M (-4.7% total)-0.99%2021-06-30 → 2026-06-3074M → 70.4M (-4.9% total)-0.40%2016-06-30 → 2026-06-3073.2M → 70.4M (-3.9% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +17.16%2025-06-30 → 2026-06-30$6.67 → $7.82 (+17.2% total)+4.44%2023-06-30 → 2026-06-30$6.86 → $7.82 (+13.9% total)+2.71%2021-06-30 → 2026-06-30$6.84 → $7.82 (+14.3% total)+19.04%2016-06-30 → 2026-06-30$1.37 → $7.82 (+471.2% total)
Sales/share: +14.84%2025-06-30 → 2026-06-30$41.17 → $47.27 (+14.8% total)+6.80%2023-06-30 → 2026-06-30$38.80 → $47.27 (+21.8% total)+6.75%2021-06-30 → 2026-06-30$34.10 → $47.27 (+38.6% total)+9.06%2016-06-30 → 2026-06-30$19.86 → $47.27 (+138.0% total)
FCF/share: +29.79%2025-06-30 → 2026-06-30$4.78 → $6.21 (+29.8% total)+4.94%2023-06-30 → 2026-06-30$5.37 → $6.21 (+15.6% total)+10.12%2021-06-30 → 2026-06-30$3.83 → $6.21 (+61.9% total)+21.01%2016-06-30 → 2026-06-30$0.92 → $6.21 (+573.4% total)
Book value/share: +4.31%2025-06-30 → 2026-06-30$40.73 → $42.49 (+4.3% total)+4.54%2023-06-30 → 2026-06-30$37.19 → $42.49 (+14.3% total)+9.11%2021-06-30 → 2026-06-30$27.48 → $42.49 (+54.6% total)+10.86%2016-06-30 → 2026-06-30$15.15 → $42.49 (+180.4% total)
Dividend/share: +6.09%2025-06-30 → 2026-06-30$0.84 → $0.89 (+6.1% total)+5.48%2023-06-30 → 2026-06-30$0.76 → $0.89 (+17.4% total)+5.71%2021-06-30 → 2026-06-30$0.67 → $0.89 (+32.0% total)+6.33%2016-06-30 → 2026-06-30$0.48 → $0.89 (+84.7% total)
Price: +42.13%2025-09-18 → 2026-09-18$254.98 → $362.31 (+42.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.81%2023-09-18 → 2026-09-18$394.60 → $362.31 (-8.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-4.18%2021-09-17 → 2026-09-18$448.62 → $362.31 (-19.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+16.10%2016-09-16 → 2026-09-18$81.39 → $362.31 (+345.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +42.57%2025-09-18 → 2026-09-18$254.19 → $362.31 (+42.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-2.53%2023-09-18 → 2026-09-18$391.24 → $362.31 (-7.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-3.93%2021-09-17 → 2026-09-18$442.77 → $362.31 (-18.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+16.52%2016-09-16 → 2026-09-18$78.48 → $362.31 (+361.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 46.3×2016-09 39.572026-09 45.14+14.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 37.5×2016-09 29.052026-09 37.47+29.0% over the window
Fwd P/E: 36.3×
P/S (ttm)Market cap ÷ TTM revenue.: 7.7×2016-09 3.672026-09 7.66+109.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 8.5×2016-09 4.772026-09 8.53+78.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 58.4×2016-09 113.352026-09 58.36-48.5% over the window
EV/EBITDA (fy): 29.4×
EV/Sales (ttm): 7.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 1.71%2016-06 1.2%2026-06 1.7%+40.7% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 0.24%
Dividend/share (fwd): $0.89
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 70.4M ÷ 71.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 2.13%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (2.13%) + dividends paid over that year ($62.4M) ÷ market_cap_at(2025-06-30) ($15.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 2.53%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($454.3M) ÷ today's market cap ($25.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.78%2016-06 0.3%2026-06 1.8%+474.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $454.3M + TTM dividends $62.4M) ÷ today's market cap ($25.5B). Same caveat as the cash buyback yield.: 2.03%2016-06 0.9%2026-06 2.1%+118.9% over the window

Vs own 10Y history

P/E: 54th
P/OI: 60th
P/S: 59th
P/B: 59th
P/FCF: 46th

Bar = where today’s multiple sits in WST’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-1.17%

+4.64%

+4.54%

+10.48%

YTD

+31.68%

+42.09%

-19.24%

Financial statements

Open full WST financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-5.94%	+0.04%
JNJ	Johnson & Johnson	-0.41%	-0.09%
ABBV	AbbVie Inc.	+1.95%	-0.02%
MRK	Merck & Co. Inc.	+8.66%	-0.19%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-4.32%	+0.45%
TMO	Thermo Fisher Scientific Inc.	+10.60%	-1.04%
AMGN	Amgen Inc.	-9.32%	+1.55%
GILD	Gilead Sciences Inc.	+4.65%	-0.52%

West Pharmaceutical Services Inc. (WST) trades at $362.31 with a live price and an interactive chart covering 46+ years of daily price history, plus key valuation metrics. ChartRow also publishes WST’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full WST financial statements →

WST — West Pharmaceutical Services Inc. price, chart and key statistics